Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Reimbursement News In Brief

This article was originally published in The Gray Sheet

Executive Summary

Genzyme keeps separate HCPCS code: Genzyme's Synvisc hyaluronic acid-based product for treating osteoarthritic knee joints will continue to be paid at a higher rate than competing products in 2006, the firm announced Nov. 8. The decision maintains the 2005 rates and reverses CMS' proposal to place all viscosupplement products in the same J-code. Synvisc competes with Johnson & Johnson/Ortho Biotech'sOrthovisc, Sanofi-Aventis' Hyalgan and Smith & Nephew's Supartz (1"The Gray Sheet" June 20, 2005, p. 3). Orthovisc will continue to be paid using miscellaneous codes, according to the firm...

You may also be interested in...



Private Comparative Effectiveness Arbiter Is In Industry’s Interest – Attorney

Industry should develop a third-party comparative effectiveness review organization to preclude Congress from creating a similar body, Sidley Austin Brown & Wood partner Patrick Morrisey said Dec. 5

Private Comparative Effectiveness Arbiter Is In Industry’s Interest – Attorney

Industry should develop a third-party comparative effectiveness review organization to preclude Congress from creating a similar body, Sidley Austin Brown & Wood partner Patrick Morrisey said Dec. 5

Osteoarthritis Knee-Treatment Device Firms Clash Over Physician Fees

Genzyme is urging CMS to retain a single HCPCS procedure billing code for the three hyaluronic acid-based devices competing with its Synvisc

Related Content

UsernamePublicRestriction

Register

MT022907

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel